- Codexis and Arch Pharmalabs expand collaboration (Pharmaceutical Business Review)
Codexis and Arch Pharmalabs have announced a major new strategic collaboration, expanding their three-year partnership in pharmaceuticals manufacturing.
- Intellectual Property (Mondaq)
Don't rush into signing NDA's. Sometimes it's better not to, particularly if you may end up receiving information that you already have, or being bound not to compete with something you already knew about. Instead, fully understand the meets and bounds of what you can say and speak to these.
- Codexis, Arch Announce Expanded Collaboration (PharmaceuticalOnline)
Codexis, Inc., a leader in biocatalysis technology, and Arch Pharmalabs Limited, a leading Indian active pharmaceutical ingredients (APIs) and intermediates manufacturer, recently announced a major new strategic collaboration, expanding their three-year partnership in pharmaceuticals manufacturing.
- CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar ... (Business Wire via Yahoo! Finance)
MEXICO CITY----Please replace the release with the following corrected version due to multiple revisions.
- POZEN To Present at the 3rd Annual Citi Biotech Day (Business Wire via Yahoo! Finance)
CHAPEL HILL, N.C.----POZEN Inc. announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. in New York City.
- CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable ... (Business Wire via Yahoo! Finance)
MEXICO CITY----Bristol-Myers Squibb Company today announced results from a pre-specified subanalysis of the CASTLE study, in which once-daily boosted REYATAZ® and twice-daily co-formulated lopinavir 400 mg and ritonavir 100 mg , each as part of HIV combination therapy, showed similar results for undetectable viral load at 48 weeks regardless of gender in treatment-naïve HIV-1 infected adults.